Total medical devices industry venture financing deals in July 2019 worth $540.5m were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 14.5% over the previous month and a drop of 5.5% when compared with the last 12-month average of $572.07m.
The US held an 83.2% share of the global medical devices industry venture financing deal value that totalled $649.89m in July 2019.
In terms of deal activity, the US recorded 50 deals during July 2019, marking a decrease of 24.2% over the previous month and a drop of 7.4% over the 12-month average.
The US medical devices industry venture financing deals in July 2019: Top deals
The top five medical devices industry venture financing deals accounted for 58.7% of the overall value during July 2019.
The combined value of the top five medical devices venture financing deals stood at $317m, against the overall value of $540.5m recorded for the month.
The top five medical devices industry deals of July 2019 tracked by GlobalData were:
1) American Cancer Society, Andreessen Horowitz, Data Collective Venture Capital, Verily Life Sciences, GV Management Co, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, Section 32 and T. Rowe Price Associates’ $160m venture financing of Freenome
2) The $63m venture financing of Beta Bionics by ArrowMark Partners, Eventide Asset Management, Farallon Capital Management, Perceptive Advisors, RTW Investments and Soleus Capital Management
3) Perceptive Advisors, RTW Investments, Soleus Capital Management, SternAegis Ventures and Terumo’s $34m venture financing of Orchestra BioMed
4) The $30m venture financing of Procyrion by Bluebird Merchant Ventures, Fannin Partners, Scientific Health Development and State of Texas
5) Mithril Capital Management and Norwest Venture Partners’ venture financing of Neocis for $30m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.